MARKET

IRD

IRD

Opus Genetics
NASDAQ
4.200
+0.020
+0.48%
After Hours: 4.150 -0.05 -1.19% 19:30 11/09 EST
OPEN
4.240
PREV CLOSE
4.180
HIGH
4.365
LOW
4.154
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
1.700
MARKET CAP
349.42M
P/E (TTM)
-3.2530
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IRD last week (1102-1106)?
Weekly Report · 18h ago
Analysts’ Opinions Are Mixed on These NA Stocks: Pan American Silver (PAAS), Opus Genetics (IRD) and Blue Owl Technology Finance Corp. (OTF)
TipRanks · 4d ago
Opus Genetics completes dosing in higher-dose Cohort 2 of BIRD-1 trial
TipRanks · 4d ago
Weekly Report: what happened at IRD last week (1026-1030)?
Weekly Report · 11/02 09:58
Press Release: Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Dow Jones · 10/29 11:00
Have Opus Genetics Insiders Been Selling Stock?
Simply Wall St · 10/29 10:11
Weekly Report: what happened at IRD last week (1019-1023)?
Weekly Report · 10/26 09:58
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
NASDAQ · 10/25 12:02
More
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Webull offers Opus Genetics Inc stock information, including NASDAQ: IRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRD stock methods without spending real money on the virtual paper trading platform.